Body Location or Region – Page 3

Actionable Insights Powered by AI

Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO

2 years ago talkbio0Tagged Arch of foot, Backed, Bayer, bleomycin/dacarbazine/lomustine/vincristine, Boundless, Checkpoint Kinase 1 Inhibitors, extrachromosomal DNA, IPO, Nasdaq Listing, Oncology Startup, Partner in relationship, Phase 1 Trials, Preliminary, Public Offering, Second Half of 2024, small molecule drugs, symbol

Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024

UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta

2 years ago talkbio0Tagged Cystic Fibrosis, next-gen, Records, Trikafta, vanza

Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records